Oncology Medical Affairs Residency at Eli Lilly and Company

Toronto, Ontario, Canada

Apply Now

Not SpecifiedCompensation

Internship, Entry Level & New GradExperience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, Healthcare, OncologyIndustries

Requirements

Recent pharmacy graduate
Interest in Medical Affairs and the pharmaceutical industry, with a focus on the Oncology therapeutic area
Fully vaccinated against COVID-19, including any approved boosters as per Lilly’s Covid-19 Vaccination Policy

Responsibilities

Build partnerships with Medical Advisors, MSLs, Medical Information, and Medical Education to support evidence-based use of Lilly’s oncology medicines and develop/implement tactics of strategic importance to the medical plan
Collaborate with MSLs to interpret field insights and capture/communicate competitive intelligence with relevant cross-functional partners
Contribute to the development and communication of the MSL field plan, medical plan, business plan, and thought leader engagement plan
Provide cross-functional support to internal stakeholders (e.g., marketing, pricing reimbursement and access, clinical operations, and regulatory affairs)
Contribute to pre-launch planning efforts for upcoming assets, including gaining understanding of patients’ unmet needs and medical journeys in relevant therapeutic areas

Skills

Key technologies and capabilities for this role

PharmacyOncologyMedical AffairsMSLMedical Strategic PlanCompetitive IntelligenceThought Leader EngagementMedical InformationMedical Education

Questions & Answers

Common questions about this position

What is the work arrangement for this residency?

This role is a flexible worker position with on-site presence in the Toronto office expected to be 4-12 days per month, as determined by your manager and business needs.

Who is eligible to apply for this residency?

This opportunity is open to recent pharmacy graduates with an interest in Medical Affairs who wish to explore the pharmaceutical industry with a focus on the Oncology therapeutic area.

What are the primary responsibilities of this role?

Responsibilities include building partnerships with Medical Advisors, MSLs, and others to support evidence-based use of oncology medicines, collaborating with MSLs on field insights and competitive intelligence, contributing to medical and business plans, providing cross-functional support, and assisting with pre-launch planning.

What is the duration and location of this residency?

It is a one-year Medical Affairs Oncology residency in partnership with the Leslie Dan Faculty of Pharmacy, University of Toronto for the 2024-2025 year, based in Toronto.

How do I apply for this residency?

To apply or for more information, contact the Industrial Pharmacy Residency Program at the Leslie Dan Faculty of Pharmacy, University of Toronto via Pharm.residency@utoronto.ca or visit their website.

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free